Business
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Additional details will be available on the Investor Relations section of the Com
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KH8PPWGWgkhj4V41vXuuLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Additional details will be available on the Investor Relations section of the Company’s website at https://ir.renovorx.com/.","length":543,"tagName":"p"},{"type":"text","content":"During the call, RenovoRx’s management is expected to highlight positive commercial momentum, including progress in achieved sales of RenovoCath as a stand-alone device in U.S. cancer centers and stronger presence in major high-volume institutions, along with rising repeat orders from current customers.","length":304,"tagName":"p"},{"type":"text","content":"Management will also provide an update on its clinical program developments, including the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer. TIGeR-PaC is nearing full enrollment and remains on track for completion in the first half of 2026, with final data anticipated in 2027. The Company will outline its strategy for generating new data through post-marketing registry studies in solid tumors and continued support of investigator-initiated trials (IITs) in borderline resectable and metastatic pancreatic cancer, along with exploring physician interest in other therapeutic areas. Registry and IIT studies achieve cost neutrality as capital-efficient studies providing meaningful data that may further broaden the application for the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform.","length":819,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"styl...